UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.726

Sortiert nach

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Annals of oncology, 2014-12, Vol.25 (12), p.2357-2362

2014

Link zum Volltext

Verfügbarkeit prüfen

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of oncology, 2014-04, Vol.25 (4), p.808-815

2014

Link zum Volltext

Verfügbarkeit prüfen

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

Annals of oncology, 2019-02, Vol.30 (2), p.325-331

2019

Link zum Volltext

Verfügbarkeit prüfen

Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs

Oncogene, 2009-08, Vol.28 (S1), p.S4-S13

Burris, 3rd, H A

2009

Link zum Volltext

Verfügbarkeit prüfen

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

Annals of oncology, 2015-01, Vol.26 (1), p.58-64

2015

Link zum Volltext

Verfügbarkeit prüfen

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Journal of clinical oncology, 1997-06, Vol.15 (6), p.2403-2413

1997

Link zum Volltext

Verfügbarkeit prüfen

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

Annals of oncology, 2003-12, Vol.14 (12), p.1735-1743

2003

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

British journal of cancer, 2014-05, Vol.110 (11), p.2647-2654

2014

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma

Annals of oncology, 2014-09, Vol.25 (9), p.1794-1799

2014

Link zum Volltext

Verfügbarkeit prüfen

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of oncology, 2018-07, Vol.29 (7), p.1541-1547

2018

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network

Journal of clinical oncology, 2001-06, Vol.19 (12), p.3018-3024

2001

Link zum Volltext

Verfügbarkeit prüfen

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

Annals of oncology, 2017-04, Vol.28 (4), p.855-861

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

Journal of clinical oncology, 1998-06, Vol.16 (6), p.2164-2168

1998

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer

Journal of clinical oncology, 1995-12, Vol.13 (12), p.2879-2885

1995

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Annals of oncology, 1996-04, Vol.7 (4), p.347-353

1996

Link zum Volltext

Verfügbarkeit prüfen

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer

Annals of oncology, 2013-08, Vol.24 (8), p.2005-2011

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer

Journal of clinical oncology, 1996-04, Vol.14 (4), p.1128-1135

1996

Link zum Volltext

Verfügbarkeit prüfen

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2012, Vol.69 (1), p.165-172

2012

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

Journal of clinical oncology, 1998-10, Vol.16 (10), p.3362-3368

1998

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer

Journal of clinical oncology, 1998-01, Vol.16 (1), p.187-196

1998

Link zum Volltext

Verfügbarkeit prüfen

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma : A minnie pearl cancer research network Phase II trial

Cancer, 2000-07, Vol.89 (2), p.328-333

2000

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

Annals of oncology, 2016-11, Vol.27 (11), p.2124-2130

2016

Link zum Volltext

Verfügbarkeit prüfen

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of oncology, 2019-11, Vol.30 (11), p.1842-1842

2019

Link zum Volltext

Verfügbarkeit prüfen

Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin

Annals of oncology, 2000-02, Vol.11 (2), p.211-215

2000

Link zum Volltext

Verfügbarkeit prüfen

Phase I and pharmacokinetic trial of weekly CPT-11

Journal of clinical oncology, 1993-11, Vol.11 (11), p.2194-2204

1993

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.726

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.567)
Mit Volltextzugriff
(1.489)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.724)
Japanisch
(119)
Croatian
(1)
Französisch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma : A minnie pearl cancer research network Phase II trial

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin

Phase I and pharmacokinetic trial of weekly CPT-11

Suchergebnisse filtern